Consistent improvement with eculizumab across muscle groups in myasthenia gravis

OBJECTIVE: To assess whether eculizumab, a terminal complement inhibitor, improves patient‐ and physician‐reported outcomes (evaluated using the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale, respectively) in patients with refractory anti‐acetylcho...

Descripción completa

Detalles Bibliográficos
Autores principales: Mantegazza, Renato, O'Brien, Fanny L., Yountz, Marcus, Howard, James F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448154/
https://www.ncbi.nlm.nih.gov/pubmed/32700461
http://dx.doi.org/10.1002/acn3.51121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448154/
https://www.ncbi.nlm.nih.gov/pubmed/32700461
http://dx.doi.org/10.1002/acn3.51121

Ejemplares similares